- $8.04m
- $5.64m
- $5.31m
- 24
- 41
- 35
- 24
Annual balance sheet for Biomerica, fiscal year end - May 31st, USD millions except per share, conversion factor applied.
2021 May 31st | R2022 May 31st | 2023 May 31st | 2024 May 31st | 2025 May 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 4.2 | 5.92 | 9.72 | 4.17 | 2.4 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.46 | 0.774 | 0.722 | 0.947 | 0.731 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 9.23 | 9.43 | 12.8 | 7.73 | 4.88 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.86 | 1.52 | 1.25 | 0.943 | 0.564 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 11.8 | 11.4 | 14.5 | 9.25 | 5.95 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.3 | 2.01 | 1.95 | 2.2 | 1.74 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 2.59 | 3.05 | 2.73 | 2.66 | 1.84 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 9.23 | 8.32 | 11.7 | 6.59 | 4.11 |
Total Liabilities & Shareholders' Equity | 11.8 | 11.4 | 14.5 | 9.25 | 5.95 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |